Influenza vaccination in hematopoietic SCT recipients

摘要: Influenza is a potentially serious infection after hematopoietic SCT (HSCT). Vaccination the main prophylactic approach in individuals at an increased risk for severe influenza disease or post-influenza complications. No controlled study on efficacy of vaccination has been performed HSCT recipients and also studies evaluating antibody response are limited by their small sizes that vaccinations have varying times HSCT. The reports show serological rates lower patients than healthy individuals. However, receiving vaccine 6 months later virological confirmed influenza. documentation if vaccinated earlier mostly lacking but it shown T-cell responses can be elicited vaccination. Therefore, currently available recommendations suggest starting when high, especially during ongoing community outbreaks. Two doses recommended children below age 9 years, who not previously against family members, close contacts health-care workers recommended.